Biolife Solutions (BLFS) 2.10 $BLFS
BioLife Solutions to Present at Third Annual Marcum MicroCap Conference
PR Newswire - Mon May 12, 5:00AM CDT
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues ("BioLife" or the "Company"
, today announced that management will present at the Third Annual Marcum MicroCap Conference in New York City on May 29, 2014 at the Grand Hyatt New York. Since 2012, the Marcum conference has introduced investors to promising undiscovered companies with a market capitalization of under $500 million. As part of the conference, BioLife will participate in one-on-one meetings with investors and other companies.
BioLife Solutions Announces First Quarter 2014 Results and Provides Business Update
PR Newswire - Thu May 08, 3:05PM CDT
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues ("BioLife" or the "Company" , today announced financial results for the first quarter of 2014 and a business update.
BioLife Solutions to Report Financial Results for First Quarter 2014 and Provide Business Update on May 8, 2014
PR Newswire - Tue May 06, 5:24PM CDT
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues, today announced today that the Company's first quarter 2014 financial results will be released on Thursday, May 8, 2014, and that the Company will host a conference call and live webcast at 4:30 p.m. ET that afternoon. Management will provide an overview of the Company's financial results and a general business update.
Worldwide Organ Preservation Solutions Market Overview 2013 - 2019
M2 - Thu May 01, 3:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/z5ms2f/organ) has announced the addition of the "Organ Preservation Solutions Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. Some of the prominent players in the organ preservation solutions market that have been profiled in this report include Dr. Franz K?hler Chemie GmbH, Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb, BioLife Solutions, Inc., XVIVO Perfusion AB and ToleroTech, Inc. This report studies the global organ preservation solutions market based on the various solutions available in the market in which organs are preserved, type of preservation techniques used and the major geographic markets. The global market for organ preservation solutions has been segmented into nine major solutions that include Viaspan, Custodiol HTK, Renograf, Hypothermosol, Perfadex, Lifor, HBS Solution, siRNA Transplant Solution and others (Ross-Marshall Citrate Solutions, Celsior Solution, Phosphate-Buffered Sucrose Solution, ET-Kyoto, TranSend, HetaFreeze, MaPersol and CryoStor). On the basis of preservation techniques, the market has been segmented into three categories namely hypothermic perfusion preservation (HPP), static cold storage (SCS) and others (that include normothermic preservation and oxygen insufflation techniques). Geographically, the report studies the global market with respect to four main regions, namely, North America, Europe, Asia-Pacific and Rest of the World (RoW). The market size and forecasts in terms of revenue (USD million) for the period 2011 to 2019, considering 2012 as the base year, have been provided for each solution type, technique type and geographic region. The report also provides the compounded annual growth rate (% CAGR) for the forecast period 2013 to 2019 for all the aforementioned segments. The market overview section of the report discusses the market dynamics that include drivers, restraints and opportunities influencing the market. This section also covers a market attractiveness analysis (by geography) for the year 2012 and Porter's five forces analysis for the global organ preservation solutions market. Market share (%) for the major players operating in this market has also been provided for the year 2012 in the competitive landscape section, followed by a list of recommendations for the existing and new players. The report also includes company profiles of key players operating in various segments of the market. Each company profile includes the business overview, financial overview, product portfolio, business strategies and recent developments of the respective company. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Market Overview - Aging global population - Global rate of aging population - Technological advancements - Increasing reimbursement scenario - Increase in per capita healthcare expenditure - Lack of organ donors - Widening Gap Between Patients Receiving Organ Transplants and Number of Donors in the U.S. (1998 - 2010) - High cost of procedure - Collaboration with research-oriented organizations and medical institutes to ensure retention of customer base - Porter's Five Force Analysis for the Global Organ Preservation Solutions Market Chapter 4 Global Organ Preservation Solutions Market, By Solution, 2011 - 2019 (USD Million) - Viaspan - Custodiol HTK - (Histidine-Tryptophan-Ketoglutarate) Solution - Renograf - Hypothermosol - Perfadex - Lifor - Human bioSystem (HBS) Solution - siRNA Transplant Solution - Others Chapter 5 Global Organ Preservation Solutions Market, By Preservation Technique, 2011 - 2019 (USD Million) - Hypothermic Perfusion Preservation (HPP) - Static Cold Storage (SCS) Chapter 6 Global Organ Preservation Solutions Market, By Geography, 2011 - 2019 (USD Million) Chapter 7 Competitive Landscape Chapter 8 Recommendations - Long term contracts with healthcare service providers - Broadening of distribution network - Product innovation Chapter 9 Company Profiles - 21st Century Medicine - BioLife Solutions, Inc. - BioTime, Inc. - Bristol-Myers Squibb - Claris Lifesciences Limited - CryoLife, Inc. - Dr. Franz K?hler Chemie GmbH - Lifeline Scientific - Teva Pharmaceutical Industries Ltd. - ToleroTech, Inc. - XVIVO Perfusion AB For more information visit http://www.researchandmarkets.com/research/z5ms2f/organ
Global Biopreservation Market 2013-2019 - Regenerative Medicine, Biobanking, and Drug Discovery
M2 - Wed Apr 30, 6:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8wwdmk/biopreservation) has announced the addition of the "Global Biopreservation Market 2013-2019 - Regenerative Medicine, Biobanking, and Drug Discovery" report to their offering. The emergence of biomedical research for new drugs and therapies will be one of the key factors responsible for the growth of the biopreservation market. Increasing utilization of stem cells, tissues, plasma and DNA in the research sector requires adequate storage facilities to accommodate samples and maintain their stability. Thus, equipment such as freezer, refrigerator, liquid nitrogen and consumables, along with media and laboratory information management system (LIMS) are utilized for storing biological samples. The global biopreservation market is categorized into four segments based on product type, namely freezers, refrigerators, liquid nitrogen tanks and consumables. Freezers held the majority share of the market in 2012 on account of the following factors: - Increase in plasma, cord blood and stem cell sample size - Rising number of biopreservation facilities coupled with capacity expansion in the pre-existing setups However, the global market for consumables is expected to grow at the fastest pace owing to the consistently increasing demand for cryo vials, cryo bags, cryogenic boxes, cryo tubes, gloves and other consumables from the existing biopreservation organizations. With rapid growth in the number of new bio-banks and sample size globally, the demand for consumables will rise continuously at a rapid pace during the forecast period. The global market for LIMS will also experience growth with the rising adoption of automation by storage facilities. This demand will be majorly from developed economies such as the U.S., Canada, Japan, the U.K., France and Germany. Demand from the developing economies will be sluggish initially due to high purchase and installation cost of LIMS, but will escalate with growing funding support from parent and government organizations. The media market comprises two categories, home-brew and pre-formulated media. The home-brew media segment held the majority share of the market in 2012 as it is the most preferred formulation used for storing samples. However, the demand for pre-formulated media is expected to rise rapidly during the forecast period owing to its rapid acceptance in the global biopreservation market. Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Global Biopreservation Market Overview Chapter 4 Global Biopreservation Market, by Product Type Chapter 5 Global Biopreservation Market, by Applications Chapter 6 Global Biopreservation Market, by Geography Chapter 7 Competitive Landscape Chapter 8 Recommendations Chapter 9 Company Profiles - BioCision, LLC - BioLife Solutions, Inc. - Biomatrica, Inc. - CHART MVE BIOMEDICAL - Dometic Group - LABVANTAGE Solutions, Inc. - Life Technologies Corporation - Panasonic Corporation - Qiagen N.V. - Thermo Fisher Scientific, Inc. - VWR International, LLC For more information visit http://www.researchandmarkets.com/research/8w...eservation
Aetna Inc. (AET) Worth Watching: Stock Rises 5.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 25, 7:44AM CDT
Aetna Inc. (AET) was a big mover last session, as the company saw its shares rally nearly 6.00% on the day.
BioLife Solutions to Launch biologistex(SM) Service at 20th ISCT Annual Meeting; Precision Thermal Shippers with Embedded Payload Temperature Monitoring and GPS Location Tracking
PR Newswire - Tue Apr 22, 5:00AM CDT
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues, today announced that it will launch biologistex service, a new integrated platform of a cloud-based information service and precision thermal shipping products for cells and tissues at the 20th ISCT Annual Meeting, April 23-26, 2014 in Paris, France.
BioLife Solutions announces addition of stock to Wilshire 5000 index
M2 - Mon Apr 21, 5:54AM CDT
BioLife Solutions Inc (Nasdaq:BLFS), a developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues, announced today its addition to the Wilshire 5000 Total Market Index (Wilshire 5000), effective after the markets' close on 18 April 2014, in conjunction with the monthly additions and deletions of the index.
BioLife Solutions Stock Added to the Wilshire 5000(SM)
PR Newswire - Mon Apr 21, 5:00AM CDT
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues, today announced that it was added to the Wilshire 5000 Total Market Index(SM) (Wilshire 5000(SM)) effective after the markets' close on Friday, April 18th in conjunction with the monthly additions and deletions of the index.
BioLife Solutions Announces Preliminary Q1 2014 Revenue of $2 Million
PR Newswire - Wed Apr 16, 5:00AM CDT
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues, today announced preliminary revenue of $2 million for the first quarter of 2014. Proprietary product revenue shipments were $1.13 million, representing 71% growth over the same period in 2013.
Adaptimmune Integrates BioLife Solutions CryoStor® Cell Freeze Media in Cancer Immunotherapy Clinical Trial
PR Newswire - Wed Apr 02, 5:00AM CDT
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues, today announced that Oxford, UK and Philadelphia, PA-based Adaptimmune Ltd has adopted the Company's CryoStor clinical grade cell freeze media for use in Adaptimmune's current phase I/II clinical trial CT Antigen TCR-Engineered T Cells for Myeloma.
Zacks Rank #1 Additions for Tuesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday
BioLife Solutions Closes $15.4 Million Public Offering and Converts $14.3 Million of Debt to Equity
PR Newswire - Tue Mar 25, 3:01PM CDT
BioLife Solutions, Inc. (OTCQB: BLFS) today announced that is has closed a public offering of units for gross proceeds of approximately $15.4 million at a price of $4.30 per unit, completed the conversion of $14.3 million of debt into equity and received approval to list its common stock on the NASDAQ Capital Market.
BioLife Solutions prices public offering of 3.6m units
M2 - Fri Mar 21, 6:45AM CDT
Cryopreservation solutions company BioLife Solutions (Other OTC:BLFS) reported on Thursday the planned sale of 3.6m units in a public offering.
BioLife Solutions Announces Pricing of $15.4 Million Public Offering
PR Newswire - Thu Mar 20, 8:00AM CDT
BioLife Solutions, Inc. (OTCQB: BLFS) today announced the pricing of a public offering and the entry into definitive agreements with purchasers for the sale of approximately 3.6 million units for gross proceeds to the Company of approximately $15.4 million. Each unit consists of one share of the Company's common stock and one warrant, with each whole warrant exercisable for seven years to purchase one share of the Company's common stock at an exercise price of $4.75 per share. The units are being offered at a price of $4.30 per unit.
BioLife Solutions Announces Sponsorship of Alliance for Regenerative Medicine 2nd Annual REGENMED Investor Day
PR Newswire - Mon Mar 10, 5:00AM CDT
BioLife Solutions, Inc. (OTCQB: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues, today announced that it is co-sponsoring the Alliance for Regenerative Medicine 2nd Annual REGENMED Investor Day, to be held March 26, 2014 at the Metropolitan Club in New York City.
2014 Joe Lieberman Connecticut Scholarship Fund Open for Student Applications through April 1
PR Newswire - Tue Feb 04, 7:15AM CST
Scholarship America announced today that the Joe Lieberman Connecticut Scholarship Fund, to assist outstanding high school seniors from Connecticut who plan to continue their education in college or vocational school programs, is now open for its second year of student applications.
BioLife Solutions To Be Issued New Biopreservation Patent
PR Newswire - Wed Jan 29, 10:00AM CST
BioLife Solutions, Inc. (OTCQB: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues, today announced that the United States Patent and Trademark Office has notified the Company of a new patent, to be issued on February 4, 2014.
BioLife Solutions Announces 1:14 Reverse Stock Split
PR Newswire - Tue Jan 21, 3:30PM CST
BioLife Solutions, Inc. (OTCQB: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues, today announced that pursuant to the authorization previously granted by the Company's stockholders, the Company's Board of Directors (the "Board" has fixed 1-for-14 as the ratio for its previously announced reverse stock split. The Company anticipates that the reverse stock split will be effective at the market opening on January 29, 2014. The reverse stock split is intended to facilitate the listing of BioLife's common stock on the NASDAQ Capital Market®.
LifeSci Advisors Initiates Coverage of BioLife Solutions, Inc.
Marketwire - Thu Jan 09, 8:00AM CST
LifeSci Advisors, LLC, a leading provider of investment research and investor relations services in the life sciences sector, today announced that it has initiated coverage of BioLife Solutions, Inc. (OTCBB: BLFS), a leading supplier of cGMP biopreservation media products for cells, tissues, and organs. The Company is focused on the development, manufacture, and marketing of biopreservation solutions used in the regenerative medicine, biobanking, and drug discovery markets. Current product offerings include HypoThermosol(R), CryoStor(R), and BloodStor(R), all pre-formulated, serum-free and protein-free biopreservation media and the SAVSU(R) line of precision thermal storage and shipping containers.
BioLife Solutions to Present at Third Annual Marcum MicroCap Conference
PR Newswire - Mon May 12, 5:00AM CDT
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues ("BioLife" or the "Company"
, today announced that management will present at the Third Annual Marcum MicroCap Conference in New York City on May 29, 2014 at the Grand Hyatt New York. Since 2012, the Marcum conference has introduced investors to promising undiscovered companies with a market capitalization of under $500 million. As part of the conference, BioLife will participate in one-on-one meetings with investors and other companies. BioLife Solutions Announces First Quarter 2014 Results and Provides Business Update
PR Newswire - Thu May 08, 3:05PM CDT
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues ("BioLife" or the "Company"
, today announced financial results for the first quarter of 2014 and a business update. BioLife Solutions to Report Financial Results for First Quarter 2014 and Provide Business Update on May 8, 2014
PR Newswire - Tue May 06, 5:24PM CDT
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues, today announced today that the Company's first quarter 2014 financial results will be released on Thursday, May 8, 2014, and that the Company will host a conference call and live webcast at 4:30 p.m. ET that afternoon. Management will provide an overview of the Company's financial results and a general business update.
Worldwide Organ Preservation Solutions Market Overview 2013 - 2019
M2 - Thu May 01, 3:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/z5ms2f/organ) has announced the addition of the "Organ Preservation Solutions Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. Some of the prominent players in the organ preservation solutions market that have been profiled in this report include Dr. Franz K?hler Chemie GmbH, Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb, BioLife Solutions, Inc., XVIVO Perfusion AB and ToleroTech, Inc. This report studies the global organ preservation solutions market based on the various solutions available in the market in which organs are preserved, type of preservation techniques used and the major geographic markets. The global market for organ preservation solutions has been segmented into nine major solutions that include Viaspan, Custodiol HTK, Renograf, Hypothermosol, Perfadex, Lifor, HBS Solution, siRNA Transplant Solution and others (Ross-Marshall Citrate Solutions, Celsior Solution, Phosphate-Buffered Sucrose Solution, ET-Kyoto, TranSend, HetaFreeze, MaPersol and CryoStor). On the basis of preservation techniques, the market has been segmented into three categories namely hypothermic perfusion preservation (HPP), static cold storage (SCS) and others (that include normothermic preservation and oxygen insufflation techniques). Geographically, the report studies the global market with respect to four main regions, namely, North America, Europe, Asia-Pacific and Rest of the World (RoW). The market size and forecasts in terms of revenue (USD million) for the period 2011 to 2019, considering 2012 as the base year, have been provided for each solution type, technique type and geographic region. The report also provides the compounded annual growth rate (% CAGR) for the forecast period 2013 to 2019 for all the aforementioned segments. The market overview section of the report discusses the market dynamics that include drivers, restraints and opportunities influencing the market. This section also covers a market attractiveness analysis (by geography) for the year 2012 and Porter's five forces analysis for the global organ preservation solutions market. Market share (%) for the major players operating in this market has also been provided for the year 2012 in the competitive landscape section, followed by a list of recommendations for the existing and new players. The report also includes company profiles of key players operating in various segments of the market. Each company profile includes the business overview, financial overview, product portfolio, business strategies and recent developments of the respective company. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Market Overview - Aging global population - Global rate of aging population - Technological advancements - Increasing reimbursement scenario - Increase in per capita healthcare expenditure - Lack of organ donors - Widening Gap Between Patients Receiving Organ Transplants and Number of Donors in the U.S. (1998 - 2010) - High cost of procedure - Collaboration with research-oriented organizations and medical institutes to ensure retention of customer base - Porter's Five Force Analysis for the Global Organ Preservation Solutions Market Chapter 4 Global Organ Preservation Solutions Market, By Solution, 2011 - 2019 (USD Million) - Viaspan - Custodiol HTK - (Histidine-Tryptophan-Ketoglutarate) Solution - Renograf - Hypothermosol - Perfadex - Lifor - Human bioSystem (HBS) Solution - siRNA Transplant Solution - Others Chapter 5 Global Organ Preservation Solutions Market, By Preservation Technique, 2011 - 2019 (USD Million) - Hypothermic Perfusion Preservation (HPP) - Static Cold Storage (SCS) Chapter 6 Global Organ Preservation Solutions Market, By Geography, 2011 - 2019 (USD Million) Chapter 7 Competitive Landscape Chapter 8 Recommendations - Long term contracts with healthcare service providers - Broadening of distribution network - Product innovation Chapter 9 Company Profiles - 21st Century Medicine - BioLife Solutions, Inc. - BioTime, Inc. - Bristol-Myers Squibb - Claris Lifesciences Limited - CryoLife, Inc. - Dr. Franz K?hler Chemie GmbH - Lifeline Scientific - Teva Pharmaceutical Industries Ltd. - ToleroTech, Inc. - XVIVO Perfusion AB For more information visit http://www.researchandmarkets.com/research/z5ms2f/organ
Global Biopreservation Market 2013-2019 - Regenerative Medicine, Biobanking, and Drug Discovery
M2 - Wed Apr 30, 6:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8wwdmk/biopreservation) has announced the addition of the "Global Biopreservation Market 2013-2019 - Regenerative Medicine, Biobanking, and Drug Discovery" report to their offering. The emergence of biomedical research for new drugs and therapies will be one of the key factors responsible for the growth of the biopreservation market. Increasing utilization of stem cells, tissues, plasma and DNA in the research sector requires adequate storage facilities to accommodate samples and maintain their stability. Thus, equipment such as freezer, refrigerator, liquid nitrogen and consumables, along with media and laboratory information management system (LIMS) are utilized for storing biological samples. The global biopreservation market is categorized into four segments based on product type, namely freezers, refrigerators, liquid nitrogen tanks and consumables. Freezers held the majority share of the market in 2012 on account of the following factors: - Increase in plasma, cord blood and stem cell sample size - Rising number of biopreservation facilities coupled with capacity expansion in the pre-existing setups However, the global market for consumables is expected to grow at the fastest pace owing to the consistently increasing demand for cryo vials, cryo bags, cryogenic boxes, cryo tubes, gloves and other consumables from the existing biopreservation organizations. With rapid growth in the number of new bio-banks and sample size globally, the demand for consumables will rise continuously at a rapid pace during the forecast period. The global market for LIMS will also experience growth with the rising adoption of automation by storage facilities. This demand will be majorly from developed economies such as the U.S., Canada, Japan, the U.K., France and Germany. Demand from the developing economies will be sluggish initially due to high purchase and installation cost of LIMS, but will escalate with growing funding support from parent and government organizations. The media market comprises two categories, home-brew and pre-formulated media. The home-brew media segment held the majority share of the market in 2012 as it is the most preferred formulation used for storing samples. However, the demand for pre-formulated media is expected to rise rapidly during the forecast period owing to its rapid acceptance in the global biopreservation market. Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Global Biopreservation Market Overview Chapter 4 Global Biopreservation Market, by Product Type Chapter 5 Global Biopreservation Market, by Applications Chapter 6 Global Biopreservation Market, by Geography Chapter 7 Competitive Landscape Chapter 8 Recommendations Chapter 9 Company Profiles - BioCision, LLC - BioLife Solutions, Inc. - Biomatrica, Inc. - CHART MVE BIOMEDICAL - Dometic Group - LABVANTAGE Solutions, Inc. - Life Technologies Corporation - Panasonic Corporation - Qiagen N.V. - Thermo Fisher Scientific, Inc. - VWR International, LLC For more information visit http://www.researchandmarkets.com/research/8w...eservation
Aetna Inc. (AET) Worth Watching: Stock Rises 5.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 25, 7:44AM CDT
Aetna Inc. (AET) was a big mover last session, as the company saw its shares rally nearly 6.00% on the day.
BioLife Solutions to Launch biologistex(SM) Service at 20th ISCT Annual Meeting; Precision Thermal Shippers with Embedded Payload Temperature Monitoring and GPS Location Tracking
PR Newswire - Tue Apr 22, 5:00AM CDT
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues, today announced that it will launch biologistex service, a new integrated platform of a cloud-based information service and precision thermal shipping products for cells and tissues at the 20th ISCT Annual Meeting, April 23-26, 2014 in Paris, France.
BioLife Solutions announces addition of stock to Wilshire 5000 index
M2 - Mon Apr 21, 5:54AM CDT
BioLife Solutions Inc (Nasdaq:BLFS), a developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues, announced today its addition to the Wilshire 5000 Total Market Index (Wilshire 5000), effective after the markets' close on 18 April 2014, in conjunction with the monthly additions and deletions of the index.
BioLife Solutions Stock Added to the Wilshire 5000(SM)
PR Newswire - Mon Apr 21, 5:00AM CDT
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues, today announced that it was added to the Wilshire 5000 Total Market Index(SM) (Wilshire 5000(SM)) effective after the markets' close on Friday, April 18th in conjunction with the monthly additions and deletions of the index.
BioLife Solutions Announces Preliminary Q1 2014 Revenue of $2 Million
PR Newswire - Wed Apr 16, 5:00AM CDT
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues, today announced preliminary revenue of $2 million for the first quarter of 2014. Proprietary product revenue shipments were $1.13 million, representing 71% growth over the same period in 2013.
Adaptimmune Integrates BioLife Solutions CryoStor® Cell Freeze Media in Cancer Immunotherapy Clinical Trial
PR Newswire - Wed Apr 02, 5:00AM CDT
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues, today announced that Oxford, UK and Philadelphia, PA-based Adaptimmune Ltd has adopted the Company's CryoStor clinical grade cell freeze media for use in Adaptimmune's current phase I/II clinical trial CT Antigen TCR-Engineered T Cells for Myeloma.
Zacks Rank #1 Additions for Tuesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday
BioLife Solutions Closes $15.4 Million Public Offering and Converts $14.3 Million of Debt to Equity
PR Newswire - Tue Mar 25, 3:01PM CDT
BioLife Solutions, Inc. (OTCQB: BLFS) today announced that is has closed a public offering of units for gross proceeds of approximately $15.4 million at a price of $4.30 per unit, completed the conversion of $14.3 million of debt into equity and received approval to list its common stock on the NASDAQ Capital Market.
BioLife Solutions prices public offering of 3.6m units
M2 - Fri Mar 21, 6:45AM CDT
Cryopreservation solutions company BioLife Solutions (Other OTC:BLFS) reported on Thursday the planned sale of 3.6m units in a public offering.
BioLife Solutions Announces Pricing of $15.4 Million Public Offering
PR Newswire - Thu Mar 20, 8:00AM CDT
BioLife Solutions, Inc. (OTCQB: BLFS) today announced the pricing of a public offering and the entry into definitive agreements with purchasers for the sale of approximately 3.6 million units for gross proceeds to the Company of approximately $15.4 million. Each unit consists of one share of the Company's common stock and one warrant, with each whole warrant exercisable for seven years to purchase one share of the Company's common stock at an exercise price of $4.75 per share. The units are being offered at a price of $4.30 per unit.
BioLife Solutions Announces Sponsorship of Alliance for Regenerative Medicine 2nd Annual REGENMED Investor Day
PR Newswire - Mon Mar 10, 5:00AM CDT
BioLife Solutions, Inc. (OTCQB: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues, today announced that it is co-sponsoring the Alliance for Regenerative Medicine 2nd Annual REGENMED Investor Day, to be held March 26, 2014 at the Metropolitan Club in New York City.
2014 Joe Lieberman Connecticut Scholarship Fund Open for Student Applications through April 1
PR Newswire - Tue Feb 04, 7:15AM CST
Scholarship America announced today that the Joe Lieberman Connecticut Scholarship Fund, to assist outstanding high school seniors from Connecticut who plan to continue their education in college or vocational school programs, is now open for its second year of student applications.
BioLife Solutions To Be Issued New Biopreservation Patent
PR Newswire - Wed Jan 29, 10:00AM CST
BioLife Solutions, Inc. (OTCQB: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues, today announced that the United States Patent and Trademark Office has notified the Company of a new patent, to be issued on February 4, 2014.
BioLife Solutions Announces 1:14 Reverse Stock Split
PR Newswire - Tue Jan 21, 3:30PM CST
BioLife Solutions, Inc. (OTCQB: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues, today announced that pursuant to the authorization previously granted by the Company's stockholders, the Company's Board of Directors (the "Board"
has fixed 1-for-14 as the ratio for its previously announced reverse stock split. The Company anticipates that the reverse stock split will be effective at the market opening on January 29, 2014. The reverse stock split is intended to facilitate the listing of BioLife's common stock on the NASDAQ Capital Market®. LifeSci Advisors Initiates Coverage of BioLife Solutions, Inc.
Marketwire - Thu Jan 09, 8:00AM CST
LifeSci Advisors, LLC, a leading provider of investment research and investor relations services in the life sciences sector, today announced that it has initiated coverage of BioLife Solutions, Inc. (OTCBB: BLFS), a leading supplier of cGMP biopreservation media products for cells, tissues, and organs. The Company is focused on the development, manufacture, and marketing of biopreservation solutions used in the regenerative medicine, biobanking, and drug discovery markets. Current product offerings include HypoThermosol(R), CryoStor(R), and BloodStor(R), all pre-formulated, serum-free and protein-free biopreservation media and the SAVSU(R) line of precision thermal storage and shipping containers.
